Advanced Unresectable Solid Tumors Clinical Trial
Official title:
A Phase I, Multi-center, Open-label, Single-dose Escalation and Expansion, Dose Escalation and Expansion Combination With Chemotherapy Study Evaluating the Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China
M108 is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas. The aim of this phase I study is to establish safety and Tolerability of different Dosage regimen in patients With Advanced Unresectable Solid Tumors in China.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02508441 -
Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02428712 -
A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors
|
Phase 1/Phase 2 |